Pfizer (PFE) agreed to pay about $59.7 million to settle allegations that Biohaven Pharmaceutical Holding, before being acquired by Pfizer, defrauded several US health care programs by paying kickbacks to doctors to drive prescriptions of its Nurtec ODT drug for migraine, the US Department of Justice said Friday.
According to the statement, Biohaven allegedly paid "improper remuneration" to healthcare professionals from March 1, 2020, through September 30, 2022, to induce them to prescribe Nurtec ODT and subsequently submit false claims to Medicare and other federal healthcare programs.
The Justice Department said the settlement also resolves a suit filed by a former Biohaven sales representative. However, it was noted that the settlement only resolved allegations, and no liability was determined.
Pfizer and Biohaven Pharmaceutical Holding did not immediately respond to MT Newswires' requests for comments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。